Ixekizumab: an alternative for HIV-positive psoriasis patients
Psoriasis is a recurrent and protracted inflammatory disease. Generalized erythema, plaques, and silvery scales on the surface mainly characterize its skin lesions. Biologics bring new hope to psoriasis patients. However, HIV infection is a major concern before receiving biologics. Here, we present a case of the efficacy and safety of Ixekizumab, an interleukin 17 inhibitor, in the treatment of psoriasis patients living with HIV (PPLHIV).
Authors
- Rongming Yang
- Yongzhi Han (ORCID: https://orcid.org/0000-0001-9319-9888)
- Fanghua Liu (ORCID: https://orcid.org/0000-0002-0581-1414)
- Dandan Huang (ORCID: https://orcid.org/0000-0002-6578-1835)
- Zhou Liu (ORCID: https://orcid.org/0009-0005-2981-6745)
Institutions
- Ganzhou People's Hospital (CN)
- Guangdong Academy of Medical Sciences (CN)
- Guangdong Provincial People's Hospital (CN)
Publication Details
- Journal
- AIDS Research and Therapy
- Published
- 2024-11-28
- DOI
- https://doi.org/10.1186/s12981-024-00675-8
- Citations
- 1
- Primary Topic
- Psoriasis: Treatment and Pathogenesis
- Type
- article
- Field-Weighted Citation Impact
- 0.24